(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of -9.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.62%.
Arrowhead Pharmaceuticals's revenue in 2025 is $572,976,000.On average, 7 Wall Street analysts forecast ARWR's revenue for 2026 to be $62,987,374,629, with the lowest ARWR revenue forecast at $30,554,918,550, and the highest ARWR revenue forecast at $89,424,983,340. On average, 5 Wall Street analysts forecast ARWR's revenue for 2027 to be $57,450,436,267, with the lowest ARWR revenue forecast at $41,477,265,000, and the highest ARWR revenue forecast at $75,018,546,630.
In 2028, ARWR is forecast to generate $61,335,611,679 in revenue, with the lowest revenue forecast at $47,367,036,630 and the highest revenue forecast at $75,460,970,790.